MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$25,496K
EPS
-$0.49
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-06-30
Research and development
21,491
General and administrative
7,093
Total operating expenses
28,584
Loss from operations
-28,584
Other expense
-2
Interest income
3,251
Income tax expense
0
Change in fair value of contingent value right liability
0
Total other income (expense), net
3,249
Net loss
-25,335
Net unrealized losses on marketable securities
-161
Comprehensive loss
-25,496
Basic EPS
-0.49
Diluted EPS
-0.49
Basic Average Shares
52,105,052
Diluted Average Shares
52,105,052
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$25,496K
Interest income
$3,251K
Net loss
-$25,335K
Net unrealized
losses on marketable...
-$161K
Total other income
(expense), net
$3,249K
Other expense
-$2K
Loss from operations
-$28,584K
Total operating
expenses
$28,584K
Research and development
$21,491K
General and
administrative
$7,093K
Buy us a coffee
Enliven Therapeutics, Inc. (IMRA)
Enliven Therapeutics, Inc. (IMRA)